Collaboration and license agreements - Betta Pharma License and Collaboration Agreement (Details) - USD ($) $ / shares in Units, $ in Millions				1 Months Ended
	Sep. 30, 2024	Jan. 04, 2024	May 29, 2023	Dec. 31, 2023	Dec. 31, 2025
Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Written notice period for termination of agreement			90 days
Betta Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 10.0		$ 10.0
Share Repurchase Program, Authorized, Number of Shares			5,567,928
Share Repurchase Program, Authorized, Amount			$ 25.0
Share Price			$ 4.49
Stock Repurchase Program, Premium Percentage			25.00%
Stock Repurchase Program, Duration of Trading Day Volume Weighted Average Closing Price			60 days
Stock Repurchase Program, Trading Days Prior To The Effective Date Of The Stock Purchase Agreement			2 days
Proceeds from issuance of common stock		$ 20.0
Premium from issuance of common stock		5.0
Stock ownership of company by third party					4,874,550
Estimated transaction price					$ 125.0
Transaction price from closing of the stock purchase agreement		$ 5.0
Regulatory milestone achieved				$ 2.0
Expected consideration to be received from manufactured clinical supply					$ 108.0
Betta Agreement | Research and development milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive			$ 357.0
Betta Agreement | Drug Application Approval
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount eligible to receive			$ 40.0